Patent 7846440 was granted and assigned to Merrimack Pharmaceuticals on December, 2010 by the United States Patent and Trademark Office.
The present invention provides a novel class of monoclonal antibodies which bind ErbB3 receptor and inhibits various ErbB3 functions. In a particular embodiment, the antibodies are capable of binding to ErbB3 and inhibiting ligand mediated phosphorylation of the receptor.